Up Approximately 10% Early, Low Float Nasdaq Idea (MYNZ) Could Be Inching Towards Breakout Mode

MYNZ is off to a strong start this morning. Up Approximately 10% Early, Low Float Nasdaq Idea (MYNZ) Could Be Inching Towards Breakout Mode  December 9th Dear Reader, MYNZ is off to a strong start this morning. Hitting an early high of $9.55, this Nasdaq idea is up approximately 10% at the moment. Could this be the start of something big today? After stringing together two straight green closes on Tuesday and Wednesday, this could be a great sign that MYNZ may be reaching out for previous highs. And if this low float idea is able to challenge potential resistance at the $10 level and break it down, well, watch out. Remember, this profile had [major launch news]( that you need to check out immediately. Also, check out the full MYNZ report below if you haven't already and get this Nasdaq idea on your radar quickly. ----- Mainz BioMed (NASDAQ: MYNZ) requires your immediate attention now. Here's why... The company made a major announcement this week that could be a true-game changer moving forward. At this moment, the news has flown under the radar, but maybe not for much longer. Check it out yourself: Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during CV-19 Pandemic At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany BERKELEY, Calif. and MAINZ, Germany, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days. [...] [Read the full article here.]( See what I mean? Potential game-changer. Now, to get into the nitty-gritty... Cancer screening. None of us want to go through it, but make no doubt about it... It can be a life saver. That said, with it comes the potential for a giant market. Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. (1) Recent FDA decisions suggest that screening should be conducted once every three years starting at age 45. Currently, there are 112 Million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. (1) To dive in a little deeper, check out these stats: (1) - 19 million Colonoscopies each year in USA - ~38.8% Age 50 to 75 have never been screened (in USA) - $3.7Bn Market Opportunity - 52,980 Expected deaths in US, 2021 Like I said, potential for a giant market. Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology. At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics. *Mainz BioMed (NASDAQ: MYNZ)* develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Mainz Biomed is located just west of Frankfurt in a world-renowned community for advanced DNA & Pharmaceutical research, including the home of vaccine maker BioNTech SE. The company has historical research & development collaborations with major universities, laboratories and governments across Europe. MYNZ's Flagship Product - ColoAlert (2) ColoAlert detects tumors better than the standard test (FIT) - Higher patient acceptance than FIT test. - Accurate, non-invasive, simple, safe diagnostic solution to increase patient compliance. - Proposed partnerships with clinical labs aims to speed test collection & results - Designed to offer significant advantages compared to our major competitors - Colorectal Cancer is the #2 leading killer (men & women combined) - 52,980 deaths due to CRC in USA (2021) - 5-year survival rate >90% (If detected at stage A). [Read the publication here.]( ----- Major Market Opportunity #2 - Commercial Pipeline Development – Future Product PancAlert (2) - As GenX individuals age into their 40's and 50's they become part of the age group recommended to begin testing for CRC and more. - Mainz BioMed is currently developing proprietary genetic testing methods for pancreatic cancer. - Fighting what could soon become the world’s second most deadly cancer. - Convenient stool test for at-home use. - Potential for over 50 million tests per year in Europe alone. - Supported by federal grant from Germany’s Federal Ministry for Education and Research. - Cost of goods sold (COGS) & reimbursement analogous to ColoAlert program. ----- And right now, due to several potential catalysts, MYNZ should hold the top spot on your watch-list. Here's what you need to know... No. 1 MYNZ Potential Catalyst - Low Float Profile According to the [Yahoo Finance website]( MYNZ has a low float. The website reports this profile to have approximately 11.71Mn outstanding shares total. Why is that important? It's important on one crucial level. Volatility. With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term. ----- No. 2 MYNZ Potential Catalyst - Multiple Oversold Leaning Technicals As of 1:00PM EST Wednesday, Barchart was reporting this profile to have several oversold leaning technicals. These technicals could be signaling that MYNZ is undervalued at the moment. Here is a quick [list of key technicals]( (as of 1:00PM EST Wednesday) that could signal MYNZ to be leaning oversold and packing a ton of upside potential towards a recent $18 high. - 9-Day Relative Strength Index: 43.27% - 14-Day Relative Strength Index: 44.67% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. Keep an eye on these technicals closely. ----- No. 3 MYNZ Potential Catalyst - Engaging A Leading Global Clinical Research Organization Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy BERKELEY, Calif. and MAINZ, Germany, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announced today the Company has engaged Precision for Medicine, a leading global Clinical Research Organization, to provide U.S. regulatory and reimbursement advisory support for ColoAlert, Mainz’s highly efficacious and easy-to-use diagnostic test for colorectal cancer. [...] [Read the full article here.]( ----- No. 4 MYNZ Potential Catalyst - Recent Hire Could Add Significant Value To Company Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Soren Thestrup-Nielsen M.D. to its Strategic Advisory Board. “It’s a pleasure to welcome Soren to our newly formed Strategic Advisory Board as he brings us tremendous leadership in all aspects of a product’s life cycle,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “All of us at the company are excited to work with Soren as we embark on ColoAlert’s commercial roll-out across Europe and develop the regulatory and clinical strategy for the U.S. market.” [...] [Read the full article here.]( ----- No. 5 MYNZ Potential Catalyst - Joining The Nasdaq Capital Market Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’ - Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancer - European registration completed and commercial rollout underway across multiple territories - FDA clinical study process to be launched for U.S. regulatory approval BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the Company’s ordinary shares have commenced trading on The Nasdaq Capital Market (the “Nasdaq”) under the ticker symbol “MYNZ”. [...] [Read the full article here.]( ----- Nasdaq Profile Recap: Key MYNZ Potential Catalysts To Know No. 1 - Low Float Profile No. 2 - Multiple Oversold Leaning Technicals No. 3 - Engaging A Leading Global Clinical Research Organization No. 4 - Recent Hire Could Add Significant Value To Company No. 5 - Joining The Nasdaq Capital Market ----- Coverage is officially initiated on MYNZ. When you have time later, do this: Get MYNZ on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI has been hired for a period beginning on 12/7/21 and ending on 12/9/21 to publicly disseminate information about (MYNZ) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (MYNZ). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Awareness Consulting Network LLC, StockWireNews was hired for a period beginning on 12/7/21 and ending on 12/9/21 to publicly disseminate information about (MYNZ) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (MYNZ). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net